Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

Recursion is hosting about 60 investors and analysts at its headquarters in Utah. It has generated tons of data with AI and robots, aiming to find a better way to make drugs. Recursion, which has four ...

It's not looking too good for the biotech.

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.

At a job interview on Friday, I had to write code, and one of the things that came up when we were talking about implementation of a concept was recursion. The director of the group said to me "Don't ...